Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;50(6):1912-7.
doi: 10.1128/JCM.06561-11. Epub 2012 Apr 11.

Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients

Affiliations

Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients

Adalgiza da Silva Rocha et al. J Clin Microbiol. 2012 Jun.

Abstract

Skin biopsy samples from 145 relapse leprosy cases and from five different regions in Brazil were submitted for sequence analysis of part of the genes associated with Mycobacterium leprae drug resistance. Single nucleotide polymorphisms (SNPs) in these genes were observed in M. leprae from 4 out of 92 cases with positive amplification (4.3%) and included a case with a mutation in rpoB only, another sample with SNPs in both folP1 and rpoB, and two cases showing mutations in folP1, rpoB, and gyrA, suggesting the existence of multidrug resistance (MDR). The nature of the mutations was as reported in earlier studies, being CCC to CGC in codon 55 in folP (Pro to Arg), while in the case of rpoB, all mutations occurred at codon 531, with two being a transition of TCG to ATG (Ser to Met), one TCG to TTC (Ser to Phe), and one TCG to TTG (Ser to Leu). The two cases with mutations in gyrA changed from GCA to GTA (Ala to Val) in codon 91. The median time from cure to relapse diagnosis was 9.45 years but was significantly shorter in patients with mutations (3.26 years; P = 0.0038). More than 70% of the relapses were multibacillary, including three of the mutation-carrying cases; one MDR relapse patient was paucibacillary.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Balagon MF, et al. 2009. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines. Am. J. Trop. Med. Hyg. 81:895–899 - PubMed
    1. Barnard FM, Maxwell A. 2001. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). Antimicrob. Agents Chemother. 45:1994–2000 - PMC - PubMed
    1. Brazilian Ministry of Health (Brasil Ministério da Saúde)/SVS 2009. Monitoramento das recidivas e da resistência medicamentosa em hanseníase no Brasil, nota técnica no. 05/2009PNCH/SVS/MS Brazilian Ministry of Health, Federal District, Brazil
    1. Brazilian Ministry of Health (Brasil Ministério da Saúde)/SVS 2010. Instruções Normativas das ações de controle da hanseníase no SUS. Portaria no. 3.125/SVS-SAS. Brazilian Ministry of Health, Federal District, Brazil
    1. Cambau E, et al. 2002. Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin. Infect. Dis. 34:39–45 - PubMed

Publication types

MeSH terms